Academic Journal
Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology
| العنوان: | Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology |
|---|---|
| المؤلفون: | Calleja, José Luis, Rivera Esteban, Jesus Manuel, Aller, Rocío, Abad, Javier, Pericàs Pulido, Juan Manuel, Hernandez Conde, Marta, Augustin Recio, Salvador |
| المساهمون: | Institut Català de la Salut, Calleja JL, Hernández-Conde M, Abad J Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro, School of Medicine, Universidad Autónoma Madrid, IDIPHIM, Majadahonda, Spain. Rivera-Esteban J Unitat Hepàtica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Aller R Department of Gastroenterology, Clinic University Hospital, Medical School, Group of Biomedical Research in Critical Care Medicine (BioCritic), University of Valladolid, Valladolid, Spain. Research Unit, Clinic University Hospital, Medical School, Institute of Health Sciences of Castille and Leon (IECSCYL), Group of Biomedical Research in Critical Care Medicine (BioCritic), Valladolid, Spain. Pericàs JM Unitat Hepàtica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Augustin S Unitat Hepàtica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Therapeutic Area Cardio-Metabolism and Respiratory Medicine, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Scientia |
| بيانات النشر: | Wiley |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Esteatosi hepàtica - Epidemiologia, Fetge - Fibrosi - Imatgeria, Esteatosi hepàtica - Imatgeria, DISEASES::Digestive System Diseases::Liver Diseases::Fatty Liver::Non-alcoholic Fatty Liver Disease, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Ultrasonography::Elasticity Imaging Techniques, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence, ENFERMEDADES::enfermedades del sistema digestivo::enfermedades hepáticas::hígado graso::esteatosis hepática no alcohólica, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::ecografía::elastografía, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::estadísticas vitales::morbilidad::prevalencia |
| الوصف: | Hepatic fibrosis; Non-alcoholic steatohepatitis; Transient elastography ; Fibrosis hepática; Esteatohepatitis no alcohólica; Elastografía transitoria ; Fibrosi hepàtica; Esteatohepatitis no alcohòlica; Elastografia transitòria ; Background & Aims Non-alcoholic fatty liver disease (NAFLD) has become a major public health problem, but the prevalence of fibrosis associated with non-alcoholic steatohepatitis (NASH) is largely unknown in the general population. This study aimed to provide an updated estimation of the prevalence of NASH fibrosis in Spain. Methods This was an observational, retrospective, cross-sectional, population-based study with merged data from two Spanish datasets: a large (N = 12 246) population-based cohort (ETHON), including transient elastography (TE) data, and a contemporary multi-centric biopsy-proven NASH cohort with paired TE data from tertiary centres (N = 501). Prevalence for each NASH fibrosis stage was estimated by crossing TE data from ETHON dataset with histology data from the biopsy-proven cohort. Results From the patients with valid TE in ETHON dataset (N = 11 440), 5.61% (95% confidence interval [95% CI]: 2.53-11.97) had a liver stiffness measurement (LSM) ≥ 8 kPa. The proportion attributable to NAFLD (using clinical variables and Controlled Attenuation Parameter) was 57.3% and thus, the estimated prevalence of population with LSM ≥ 8 kPa because of NAFLD was 3.21% (95% CI 1.13–8.75). In the biopsy-proven NASH cohort, 389 patients had LSM ≥ 8 kPa. Among these, 37% did not have significant fibrosis (F2-4). The estimated prevalence of NASH F2-3 and cirrhosis in Spain's adult population were 1.33% (95% CI 0.29–5.98) and 0.70% (95% CI 0.10–4.95) respectively. Conclusions These estimations provide an accurate picture of the current prevalence of NASH-related fibrosis in Spain and can serve as reference point for dimensioning the therapeutic efforts that will be required as NASH therapies become available. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1478-3231 |
| Relation: | Liver International;42(8); https://doi.org/10.1111/liv.15323; Calleja JL, Rivera-Esteban J, Aller R, Hernández-Conde M, Abad J, Pericàs JM, et al. Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology. Liver Int. 2022 Aug;42(8):1783–92.; https://hdl.handle.net/11351/8287; 000807259900001 |
| DOI: | 10.1111/liv.15323 |
| الاتاحة: | https://hdl.handle.net/11351/8287 https://doi.org/10.1111/liv.15323 |
| Rights: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.FF815846 |
| قاعدة البيانات: | BASE |
| تدمد: | 14783231 |
|---|---|
| DOI: | 10.1111/liv.15323 |